Mechanisms of resistance to trastuzumab in HER2-positive gastric cancer

Zhifei Li ¹Huan Zhao ²Huihui Hu ¹Haili Shang ¹Yongjing Ren ¹Wenhui Qiu ³Hao Su ⁴Huifang Lyu ⁵Xiaobing Chen¹

扫码查看

作者信息

1. Department of Oncology,the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital,Henan Engineering Research Center of Precision Therapy of Gastrointestinal Cancer,Zhengzhou Key Laboratory for Precision Therapy of Gastrointestinal Cancer,Zhengzhou 450008,China
2. Henan University of Traditional Chinese Medicine,Zhengzhou 450046,China
3. State Key Laboratory of Esophageal Cancer Prevention & Treatment,Key Laboratory of Advanced Drug Preparation Technologies,Ministry of Education,School of Pharmaceutical Sciences,Zhengzhou University,Zhengzhou 450001,China
4. The First Affiliated Hospital of Xinxiang Medical University,Xinxiang 453000,China
5. Department of Oncology,the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital,Zhengzhou 450008,China
折叠

Abstract

Gastric cancer is one of the most prevalent cancers worldwide,and human epidermal growth factor receptor 2(HER2)-positive cases account for approximately 20％of the total cases.Currently,trastuzumab+chemotherapy is the recommended first-line treatment for patients with HER2-positive advanced gastric cancer,and the combination has exhibited definite efficacy in HER2-targeted therapy.However,the emergence of drug resistance during treatment considerably reduces its effectiveness;thus,it is imperative to investigate the potential mechanisms underlying resistance.In the present review article,we comprehensively introduce multiple mechanisms underlying resistance to trastuzumab in HER2-positive gastric cancer cases,aiming to provide insights for rectifying issues associated with resistance to trastuzumab and devising subsequent treatment strategies.

Key words

HER2/gastric cancer/trastuzumab/drug resistance

引用本文复制引用

基金项目

Project of Henan Provincial Medical Science and Technology Research Plan(SBGJ202301004)

Project of Henan Provincial Medical Science and Technology Research Plan(LHGJ20210186)

Key Science Fund project of Henan Provincial Natural Science Foundation(232300421119)

出版年

2024

中国癌症研究(英文版)

中国抗癌协会北京市肿瘤研究所

中国癌症研究(英文版)

CSTPCDCSCD

影响因子：1.592

ISSN：1000-9604

参考文献量119

段落导航